COLL Q2 2024 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q2 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$145M+7.2% YoY

Gross Profit

$91M62.5% margin

Operating Income

$47M32.7% margin

Net Income

$20M13.5% margin

EPS (Diluted)

$0.52

QoQ Revenue Growth

+0.2%

Cash Flow

Operating Cash Flow

$67M

Free Cash Flow

$67M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$837M

Stockholders' Equity

$217M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$136M	+7.2%
Gross Profit	$91M	$74M	+23.0%
Operating Income	$47M	$36M	+33.2%
Net Income	$20M	$13M	+50.7%

Revenue Segments

Belbuca

$52M36%

Xtampza ER

$45M31%

Nucynta IR

$25M17%

Nucynta ER

$19M13%

Symproic

$4M3%